Axogen Inc

Healthcare US AXGN

11.435USD
0.07(0.66%)

Last update at 2025-07-08T16:45:00Z

Day Range

11.1511.70
LowHigh

52 Week Range

5.5515.90
LowHigh

Fundamentals

  • Previous Close 11.36
  • Market Cap645.60M
  • Volume330680
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.84800M
  • Revenue TTM180.86M
  • Revenue Per Share TTM4.16
  • Gross Profit TTM 114.44M
  • Diluted EPS TTM-0.33

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -28.94800M -26.98500M -23.78600M -29.13500M -22.39700M
Minority interest - - - - -
Net income -27.33500M -28.06300M -24.80200M -29.12200M -22.39700M
Selling general administrative 36.76M 32.34M 26.40M 31.30M 23.12M
Selling and marketing expenses 80.23M 73.33M 69.66M 71.95M 56.62M
Gross profit 114.44M 104.43M 90.72M 89.36M 71.01M
Reconciled depreciation 4.85M 4.74M 3.46M 2.88M 0.85M
Ebit -29.70700M -25.41600M -23.18200M -31.40600M -20.52800M
Ebitda -25.08400M -20.95300M -19.76000M -26.21800M -19.67700M
Depreciation and amortization 4.62M 4.46M 3.42M 5.19M 0.85M
Non operating income net other 1.38M -0.21300M 0.45M - -0.77000M
Operating income -29.70700M -25.41600M -23.18200M -31.40600M -20.50000M
Other operating expenses 168.29M 152.77M 135.48M 138.12M 104.44M
Interest expense 0.62M 1.36M 1.05M 0.04M 1.21M
Tax provision - - - - -
Interest income - - - 2.36M 0.32M
Net interest income -0.62400M -1.35600M -1.05400M -0.04000M -1.20800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.61300M 1.08M 1.02M -0.01300M 0.66M
Total revenue 138.58M 127.36M 112.30M 106.71M 83.94M
Total operating expenses 144.14M 129.84M 113.90M 120.77M 91.51M
Cost of revenue 24.15M 22.93M 21.58M 17.35M 12.92M
Total other income expense net 0.76M -1.56900M -0.60400M 2.27M -0.68900M
Discontinued operations - - - - -
Net income from continuing ops -28.94800M -26.98500M -23.78600M -29.13500M -22.39700M
Net income applicable to common shares -28.94800M -26.98500M -23.78600M -29.13500M -22.39700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 196.83M 195.39M 208.02M 201.38M 154.64M
Intangible assets 4.53M 3.65M 2.86M 2.05M 1.51M
Earning assets - - - - -
Other current assets 2.81M 1.94M 1.86M 4.30M 1.71M
Total liab 101.16M 94.39M 95.47M 78.23M 22.49M
Total stockholder equity 95.67M 101.00M 112.55M 123.15M 132.15M
Deferred long term liab - 4.52M 5.56M 2.50M -
Other current liab 17.11M 13.48M 16.54M 17.37M 10.87M
Common stock 0.43M 0.42M 0.42M 0.41M 0.40M
Capital stock 0.43M 0.42M 0.42M 0.41M 0.40M
Retained earnings -281.29600M -259.58000M -230.63200M -203.64700M -179.86100M
Other liab - - - 0.00300M 0.01M
Good will - - - - -
Other assets - - - 0.00100M -
Cash 37.03M 15.28M 32.76M 48.77M 35.72M
Cash and equivalents - - - - -
Total current liabilities 30.43M 23.75M 24.29M 22.83M 20.88M
Current deferred revenue - - - - 0.01M
Net debt 32.27M 52.14M 34.70M 5.00M -32.39300M
Short term debt 1.55M 1.31M 1.83M 0.86M 1.74M
Short long term debt - - - 0.86M 1.74M
Short long term debt total 69.29M 67.43M 67.45M 53.76M 3.33M
Other stockholder equity 376.53M 360.15M 342.76M 326.39M 311.62M
Property plant equipment - 93.66M 78.12M 38.40M 18.11M
Total current assets 88.00M 98.08M 127.05M 145.25M 135.02M
Long term investments - - - - -
Net tangible assets - 97.35M 109.69M 121.09M 130.64M
Short term investments 0.00000M 33.51M 51.33M 55.20M 60.79M
Net receivables 25.15M 22.19M 18.16M 17.62M 16.94M
Long term debt 46.60M 66.12M 65.62M 52.90M 1.59M
Inventory 23.02M 18.91M 16.69M 12.53M 13.86M
Accounts payable 11.77M 8.96M 5.92M 4.60M 8.26M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -3.76400M
Additional paid in capital - - - - -
Common stock total equity - 0.42M 0.42M 0.41M 0.40M
Preferred stock total equity - - - - -
Retained earnings total equity - -259.58000M -230.63200M -203.64700M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 93.66M 0.04M 15.68M 19.62M
Deferred long term asset charges - - - - -
Non current assets total 108.82M 97.31M 80.97M 56.13M 19.62M
Capital lease obligations 22.69M 21.71M 22.63M 20.87M -
Long term debt total - 66.12M 65.62M 52.90M 0.03M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 18.32M 18.05M 3.80M 5.63M 27.27M
Change to liabilities - 0.66M -0.27300M 4.96M 2.89M
Total cashflows from investing activities - -3.20000M -23.64900M -16.96300M 27.27M
Net borrowings - -0.01200M 14.98M 35.00M 0.03M
Total cash from financing activities 1.95M 1.79M 20.45M 40.47M 4.03M
Change to operating activities - -1.92700M 1.97M -3.61300M -2.43800M
Net income -21.71600M -28.94800M -26.98500M -23.78600M -29.13500M
Change in cash 15.49M -17.47200M -16.60200M 13.88M 11.43M
Begin period cash flow 21.54M 39.01M 55.61M 41.72M 30.29M
End period cash flow 37.03M 21.54M 39.01M 55.61M 41.72M
Total cash from operating activities -5.71600M -16.06600M -13.40500M -9.62600M -19.87200M
Issuance of capital stock - 0.00000M 0.00000M 3.50M 7.82M
Depreciation 5.55M 4.85M 4.74M 3.46M 2.88M
Other cashflows from investing activities - -1.17500M 0.95M -0.69200M 32.50M
Dividends paid - - - 0.67M -
Change to inventory -6.05400M -3.65600M -7.47800M -0.91000M -3.76700M
Change to account receivables -2.69100M -4.63900M -0.49900M -0.63500M -2.13600M
Sale purchase of stock - 1.81M 5.47M -0.67000M 4.00M
Other cashflows from financing activities 1.96M 1.81M 5.47M 1.99M 0.06M
Change to netincome - 16.70M 14.29M 10.68M 11.84M
Capital expenditures 14.92M 21.25M 28.40M 22.60M 121.64M
Change receivables - -4.63900M -0.49900M -0.63500M -
Cash flows other operating - -0.16600M 3.79M -1.82500M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - -17.47200M -16.60200M 13.88M -
Change in working capital -4.38600M -9.56000M -6.27800M -0.20900M -6.41900M
Stock based compensation 14.42M 15.59M 10.92M 8.47M 10.30M
Other non cash items 0.41M 2.00M 0.83M 0.23M 2.50M
Free cash flow -20.63400M -37.31900M -41.80500M -32.22300M -141.50800M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AXGN
Axogen Inc
0.07 0.66% 11.44 - 41.49 3.57 6.60 3.87 408.21
ABT
Abbott Laboratories
0.33 0.25% 134.03 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation
-1.835 0.47% 390.68 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
0.76 0.87% 88.43 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
-1.685 1.62% 102.14 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.

Axogen Inc

13631 Progress Boulevard, Alachua, FL, United States, 32615

Key Executives

Name Title Year Born
Ms. Karen Zaderej Chairman, Pres & CEO 1962
Mr. Peter J. Mariani Exec. VP & CFO 1964
Ms. Maria D. Martinez Chief HR Officer 1968
Mr. Angelo G. Scopelianos Ph.D. Chief R&D Officer 1955
Mr. Michael Donovan VP of Operations 1965
Ed Joyce Director of Investor Relations NA
Mr. Bradley L. Ottinger J.D. Gen. Counsel & Chief Compliance Officer 1970
Mr. Gregory Davault VP of Marketing 1968
Ms. Doris Quackenbush VP of Sales NA
Ms. Isabelle Billet Chief Strategy & Bus. Devel. Officer 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.